bf/NASDAQ:KRYS_icon.jpeg

NASDAQ:KRYS

Krystal Biotech, Inc.

  • Stock

165.69

−2.47%

15.42

USD last updated 16/08 01:55:59

Last Close

150.27

15/08 20:01

Market Cap

5.52B

Beta: 0.85

Volume Today

257.13K

Avg: 203.48K

PE Ratio

−105.15

PFCF: −26.48

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clini...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -2-1122017-03-312019-03-122021-03-012023-02-272024-08-05

    Revenue (Estimate*)

    20M40M60M80M100M2017-03-312019-03-122021-03-012023-02-272024-08-05

    *Estimate based on analyst consensus